Health1 min read

STAT+: With $173 million, new startup takes aim at sickle cell

By · Via STAT Health · Published by Everything Blog

In short

Marrow Therapeutics launched with substantial venture support to create an improved treatment option for sickle cell disease. Founded by biotech entrepreneur Romesh Subramanian, the company hopes to match the clinical power of existing gene therapies while sidestepping their known downsides. The startup secured $173 million through combined Series A and Series B funding rounds backed by OrbiMed, venBio, and Scion Life Sciences. Although Subramanian acknowledges the scientific approach still requires clinical validation, expectations remain high for its performance.

Key points

  • Marrow Therapeutics aims to match gene therapy effectiveness while avoiding the drawbacks…: Marrow Therapeutics aims to match gene therapy effectiveness while avoiding the drawbacks linked to it.
  • The company faces the critical challenge of clinically proving its novel therapeutic appr…: The company faces the critical challenge of clinically proving its novel therapeutic approach in patients.
  • Strong backing from multiple life science investors provides substantial capital for the…: Strong backing from multiple life science investors provides substantial capital for the new development effort.

Sources checked by our analysis pipeline: 1

For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks.

Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed and others.

“We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Health